While K-State and the USDA loom large, the anchor tenant and a key force to Manhattan achieving its bio-hub ambitions is the San Antonio-based third-party contractor Scorpius BioManufacturing.
The company, which develops and manufactures antibodies, vaccines and large molecule drugs for customers including the Department of Defense, DARPA and other government agencies, picked Manhattan two years ago for a new manufacturing facility.
Scorpius plans to make the anthrax antitoxin Anthim there for the U.S. Strategic National Stockpile, in addition to other medical countermeasures and traditional commercial drugs.
Scientists unveiled Tuesday a humanoid robot face they created from lab-grown, self-healing human skin.
Why it matters: The researchers from the University of Tokyo, Japan, hope the breakthrough could one day prove "useful in the cosmetics industry and to help train plastic surgeons," per a statement announcing the breakthrough.
NASA picked SpaceX to develop and deliver a spacecraft that'll bring the International Space Station out of orbit after the operational life of the ISS ends in 2030, the space agency announced Wednesday.
Why it matters: The spacecraft, which NASA is calling the U.S. Deorbit Vehicle, needs to guide the ISS safely back through Earth's atmosphere before its planned crash into the Pacific Ocean.
